<DOC>
	<DOCNO>NCT00277836</DOCNO>
	<brief_summary>MST-997 taxane analog potential treat subject variety tumor type . Preclinical data demonstrate MST-997 inhibited tumor growth administer intravenously ( IV ) . This phase 1 dose escalation study design evaluate safety tolerability IV MST-997 formulate Polysorbate 80 Diluent safely administer weekly basis .</brief_summary>
	<brief_title>Study Evaluating MST-997 Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Documented diagnosis malignant solid tumor measurable disease Life expectancy least 12 week ECOG ( Eastern Cooperative Oncology Group ) performance status 0,1 , 2 Recent major surgery , radiation therapy anticancer treatment History prior malignancy within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>malignant tumor</keyword>
</DOC>